Genmab GMAB
$50.60 −$0.75 (-1.46%)
Market closed · Nov 20, 8:20 pm ET · Last extended-hours $50.02 -1.15%
Open$51.57
Prev close$51.35
Day range$50.24 – $51.72
Volume2.90M
Market cap$31.20B
P/E (TTM)43.2
Dividend yield–
GMAB Stock News
Headlines matching Genmab or the GMAB ticker, most recent first.
- H.C. Wainwright Maintains Genmab(GMAB.US) With Buy Rating, Maintains Target Price $40
- A Quick Look at Today's Ratings for Genmab(GMAB.US), With a Forecast Between $35 to $43
- William Blair Maintains Genmab(GMAB.US) With Buy Rating
- Truist Financial Maintains Genmab(GMAB.US) With Buy Rating
- Analysts Offer Insights on Healthcare Companies: Genmab (GMAB), Definitive Healthcare Corp (DH) and Atai Beckley N.V. (ATAI)
- Morgan Stanley Maintains Genmab(GMAB.US) With Hold Rating, Maintains Target Price $33
- TD Cowen Upgrades Genmab(GMAB.US) to Buy Rating, Raises Target Price to $43 Positive
- H.C. Wainwright Maintains Genmab(GMAB.US) With Buy Rating, Raises Target Price to $40 Positive
- TD Cowen Maintains Genmab(GMAB.US) With Hold Rating, Maintains Target Price $32
- A Quick Look at Today's Ratings for Genmab(GMAB.US), With a Forecast Between $40 to $40
- Analysts Offer Insights on Healthcare Companies: Genmab (GMAB) and Hinge Health, Inc. Class A (HNGE)
- H.C. Wainwright Maintains Genmab(GMAB.US) With Buy Rating, Maintains Target Price $38
- Wells Fargo Maintains Genmab(GMAB.US) With Buy Rating, Maintains Target Price $40
- Wolfe Research Maintains Genmab(GMAB.US) With Buy Rating, Maintains Target Price $32
- Morgan Stanley Maintains Genmab(GMAB.US) With Hold Rating, Cuts Target Price to $33 Negative
No comments yet — be the first to weigh in on GMAB.
Sign in to join the discussion.